Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer
Richard S Finn, Yuan Liu, Zhou Zhu, et al.
Clinical Breast Cancer
|
December 15, 2019
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2
Hope S Rugo, Richard S Finn, Karen Gelmon, et al.
The Oncologist
|
September 19, 2025
Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study
Gabrielle B Rocque, Joanne L Blum, Yan Ji, et al.
The Oncologist
|
January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up
Richard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Journal of the National Cancer Institute
|
July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
Véronique Diéras, Hope S Rugo, Patrick Schnell, et al.
Breast Cancer Research and Treatment
|
August 13, 2020
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
Richard S Finn, Massimo Cristofanilli, Johannes Ettl, et al.
Cancer
|
April 17, 2013
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO)
Christine Chevreau, Axel Le Cesne, Isabelle Ray-Coquard, et al.
JCO Precision Oncology
|
August 18, 2025
Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study
Debu Tripathy, Joanne L Blum, Hong Zhang, et al.
The New England Journal of Medicine
|
December 14, 2016
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S Finn, Miguel Martin, Hope S Rugo, et al.
Journal of Global Oncology
|
May 25, 2019
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
Seock-Ah Im, Hirofumi Mukai, In Hae Park, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer
Richard S Finn, Yuan Liu, Zhou Zhu, et al.
Clinical Breast Cancer
|
December 15, 2019
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2
Hope S Rugo, Richard S Finn, Karen Gelmon, et al.
The Oncologist
|
September 19, 2025
Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study
Gabrielle B Rocque, Joanne L Blum, Yan Ji, et al.
The Oncologist
|
January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up
Richard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Journal of the National Cancer Institute
|
July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
Véronique Diéras, Hope S Rugo, Patrick Schnell, et al.
Breast Cancer Research and Treatment
|
August 13, 2020
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
Richard S Finn, Massimo Cristofanilli, Johannes Ettl, et al.
Cancer
|
April 17, 2013
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO)
Christine Chevreau, Axel Le Cesne, Isabelle Ray-Coquard, et al.
JCO Precision Oncology
|
August 18, 2025
Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study
Debu Tripathy, Joanne L Blum, Hong Zhang, et al.
The New England Journal of Medicine
|
December 14, 2016
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S Finn, Miguel Martin, Hope S Rugo, et al.
Journal of Global Oncology
|
May 25, 2019
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
Seock-Ah Im, Hirofumi Mukai, In Hae Park, et al.
Page
of 3